Clinical significance and expression of SLC35F6 in bladder urothelial carcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Solute carrier family 35 member F6 (SLC35F6) is upregulated in bladder cancer (BC) and linked to poorer outcomes. SLC35F6, combined with clinical factors, improves survival prediction accuracy for bladder urothelial carcinoma patients.
Area Of Science
- Molecular Biology
- Oncology
- Biochemistry
Background
- Solute carrier family 35 member F6 (SLC35F6) plays roles in mitochondrial permeability, apoptosis, and cell proliferation.
- The specific function and clinical significance of SLC35F6 in bladder cancer (BC) are not well understood.
- This study investigates SLC35F6 expression, its prognostic value, and its association with immune molecules in the BC tumor microenvironment.
Purpose Of The Study
- To evaluate the expression levels and clinical significance of SLC35F6 in bladder cancer tissues.
- To assess the prognostic value of SLC35F6 in predicting patient survival.
- To explore the relationship between SLC35F6 and key immune-related molecules within the tumor microenvironment.
Main Methods
- Combined bioinformatics analysis with immunohistochemistry (IHC) to examine SLC35F6 expression in 145 BC patient tissues.
- Chi-square tests were used to correlate SLC35F6 levels with clinicopathological factors.
- Kaplan-Meier survival curves and COX regression models analyzed prognostic values; ROC curve analysis assessed predictive performance.
Main Results
- SLC35F6 mRNA and protein expression were significantly elevated in BC tissues compared to benign tissues.
- Higher SLC35F6 protein levels correlated with a worse prognosis in BC patients.
- Multivariate analysis identified SLC35F6, TNM stage, and grade as independent risk factors for bladder cancer; combined analysis improved survival prediction accuracy for Bladder Urothelial Carcinoma (BLCA).
Conclusions
- SLC35F6 is upregulated in bladder cancer and associated with unfavorable patient prognosis.
- SLC35F6 serves as a potential prognostic and predictive biomarker for BLCA.
- Integrating SLC35F6 with existing clinical factors enhances the accuracy of survival predictions in BLCA patients.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Class I comprises GLUT1 to GLUT4 and GLUT14.
Class II has GLUT5, GLUT7,...
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...